PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2285.61%
Negative net income growth while CRON.TO stands at 135.13%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
11.96%
Less D&A growth vs. CRON.TO's 70.37%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-72.25%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
222.22%
SBC growth well above CRON.TO's 2.64%. Michael Burry would flag major dilution risk vs. competitor’s approach.
134.76%
Well above CRON.TO's 114.42% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
66.49%
AR growth while CRON.TO is negative at -313.62%. John Neff would note competitor possibly improving working capital while we allow AR to rise.
79.82%
Inventory growth well above CRON.TO's 99.70%. Michael Burry would suspect potential future write-down risk if demand does not materialize.
293.72%
AP growth well above CRON.TO's 94.19%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-127.46%
Negative yoy usage while CRON.TO is 221.95%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
1001.35%
Some yoy increase while CRON.TO is negative at -268.15%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
104.19%
Operating cash flow growth above 1.5x CRON.TO's 12.62%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-15.61%
Negative yoy CapEx while CRON.TO is 70.05%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.25%
We reduce yoy sales while CRON.TO is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
267.17%
We have some outflow growth while CRON.TO is negative at -3481.40%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-1966.65%
Both yoy lines negative, with CRON.TO at -896.67%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-70.12%
We cut debt repayment yoy while CRON.TO is 100.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Buyback growth of 100.00% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.